Integrin αv and coxsackie adenovirus receptor expression in clinical bladder cancer

被引:111
|
作者
Sachs, MD
Rauen, KA
Ramamurthy, M
Dodson, JL
De Marzo, AM
Putzi, MJ
Schoenberg, MP
Rodriguez, R
机构
[1] Johns Hopkins Univ Hosp, Brady Urol Inst, Baltimore, MD 21287 USA
[2] Humboldt Univ, Charite Med Sch, Dept Urol, Berlin, Germany
[3] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[5] Johns Hopkins Univ Hosp, Dept Surg Pathol, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA
关键词
D O I
10.1016/S0090-4295(02)01748-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To evaluate the expression of the coxsackie and adenovirus receptor (CAR) and alpha(v) integrins in clinical specimens of bladder cancer to determine the susceptibility to adenoviral gene therapy. Efficient adenovirus-based gene therapy requires binding of the virus to CAR and involves the alpha(v) integrins. Studies on bladder cancer cell lines have shown that low adenoviral transduction rates were associated with low-level expression of CAR. Integrin alpha(v) expression increases in various tumors suggest its importance in differentiation, proliferation, and migration. CAR is structurally a member of the Ig-type superfamily of cell-cell adhesion molecules, suggesting that its expression may also be related to the state of tumor differentiation. Methods. We performed immunohistochemistry for CAR and integrin alpha(v) expression in bladder cancer specimens in 50 paraffin-embedded tumor-normal pairs and confirmed the results by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of 11 separate bladder tumors and 4 separate normal bladder controls. Results. Immunochemistry demonstrated a stage and grade-dependent decrease in CAR expression (90.0%, 83.3%, and 31.3% of normal urothelium and superficial and invasive transitional cell carcinoma [TCC] and 83.3% and 39.5% of low and high-grade TCC, respectively). Furthermore, we found a stage and grade-dependent increase in alpha(v) integrin expression (13.3%, 46.0%, and 56.3% of normal urothelium, superficial TCC, and invasive TCC and 25% and 52.6% of low and high-grade TCC, respectively). Quantitative RT-PCR analysis confirmed a downregulation at the CAR gene expression level. Conclusions. This down-regulation may have a major impact on developing adenoviral-based gene therapy modalities. In addition, we propose that loss of CAR expression decreases rigid cell adhesion, possibly increasing the migratory potential. Loss of CAR expression correlates with the invasive phenotype in our analysis of bladder cancer. Simultaneously, the finding of increased alpha(v) expression in invasive cancer suggests a pathogenesis that involves heterophilic adhesion and migration of these cells on various extracellular ligands.
引用
收藏
页码:531 / 536
页数:6
相关论文
共 50 条
  • [41] Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression
    Hemminki, A
    Kanerva, A
    Liu, B
    Wang, MH
    Alvarez, RD
    Siegal, GP
    Curiel, DT
    CANCER RESEARCH, 2003, 63 (04) : 847 - 853
  • [42] Coxsackie Adenovirus Receptor (CAR) Expression and oestrogen sensitivity of the mamma carcinoma
    Auer, D.
    Reimer, D.
    Porto, V
    Wiedemair, A.
    Marth, C.
    Mueller-Holzner, E.
    Daxenbichler, G.
    Zeimet, A. G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 (04) : 431 - 431
  • [43] Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers
    H Fechner
    A Haack
    H Wang
    X Wang
    K Eizema
    M Pauschinger
    R G Schoemaker
    R van Veghel
    A B Houtsmuller
    H-P Schultheiss
    J M J Lamers
    W Poller
    Gene Therapy, 1999, 6 : 1520 - 1535
  • [44] Evaluating the expression of coxsackie adenovirus receptor in patients with renal cell carcinoma
    Okegawa, T
    Nutahara, K
    Hsieh, JT
    Higashihara, E
    JOURNAL OF UROLOGY, 2005, 173 (04): : 105 - 105
  • [46] Coxsackie-and-adenovirus receptor mRNA expression in human heart failure
    Sasse, A
    Wallich, M
    Ding, Z
    Goedecke, A
    Schrader, J
    JOURNAL OF GENE MEDICINE, 2003, 5 (10): : 876 - 882
  • [47] Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers
    Fechner, H
    Haack, A
    Wang, H
    Wang, X
    Eizema, K
    Pauschinger, M
    Schoemaker, RG
    van Veghel, R
    Houtsmuller, AB
    Schultheiss, HP
    Lamers, JMJ
    Poller, W
    GENE THERAPY, 1999, 6 (09) : 1520 - 1535
  • [48] Expression of the Coxsackie adenovirus receptor in cutaneous T-cell lymphomas
    May, Joshua
    Ledet, Jonathan
    Lowery-Nordberg, Mary
    Turturro, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (02) : AB139 - AB139
  • [49] Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies
    H S Pandha
    L H Stockwin
    J Eaton
    I A Clarke
    A G Dalgleish
    S M Todryk
    G E Blair
    Prostate Cancer and Prostatic Diseases, 2003, 6 : 6 - 11
  • [50] Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: implications for gene therapy strategies
    Pandha, HS
    Stockwin, LH
    Eaton, J
    Clarke, IA
    Dalgleish, AG
    Todryk, SM
    Blair, GE
    PROSTATE CANCER AND PROSTATIC DISEASES, 2003, 6 (01) : 6 - 11